- Molecular NameTigecycline
- SynonymGAR-936; GAR-936,Tigecycline; WAY-GAR-936
- Weight585.658
- Drugbank_IDDB00560
- ACS_NO220620-09-7
- Show 2D model
- LogP (experiment)0.217
- LogP (predicted, AB/LogP v2.0)-0.58
- pkaN/A
- LogD (pH=7, predicted)-4.13
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-3.1
- LogSw (predicted, AB/LogsW2.0)0.29
- Sw (mg/ml) (predicted, ACD/Labs)0.41
- No.of HBond Donors8
- No.of HBond Acceptors13
- No.of Rotatable Bonds6
- TPSA205.76
- StatusFDA approved
- AdministrationIV only
- PharmacologyAn glycylcycline antibiotic
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability0.0
- Protein binding80.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmTigecycline is not extensively metabolized. In vitro studies with tigecycline using human liver microsomes, liver slices, and hepatocytes led to the formation of only trace amounts of metabolites. A glucuronide, an N-acetyl metabolite, and a tigecycline epimer (each at no more than 10% of the administered dose) are the primary metabolites.
- Half life42.4 h
- Excretion59% biliary, 33% renal
- Urinary ExcretionN/A
- CleranceN/A
- ToxicitySince glycylcyclines are similar to tetracyclines, they share many of the same side effects and contraindications as tetracyclines. These side effects may include nausea/vomiting, headache, photosensitivity, discoloration of growing teeth, and fetal damage.
- LD50 (rat)N/A
- LD50 (mouse)N/A